comparemela.com

Latest Breaking News On - Robert bissonnette - Page 1 : comparemela.com

Ruxolitinib Consistent in Safety, Tolerability Over 52-Weeks in Children with Extensive Atopic Dermatitis

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.

United statesRobert bissonnetteInnovaderm researchInnovaderm research robert bissonnetteRevolutionizing atopic dermatitisMaximum use trialGlobal assessmentTreatment successDermatology life quality indexPatient oriented eczema measureInfant dermatitis quality

JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis

Researchers found that the percentage of patients with a PASI 75 response was higher among those receiving JNJ-77242113 vs placebo.

Robert bissonnetteJanssen researchInnovaderm researchHealthday newsNew england journalPsoriasis areaSeverity index

Robert Bissonnette, MD: Safety Profile, Future Research on New Oral IL-23 Inhibitor for Psoriasis

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.

Robert bissonnetteInnovaderm researchChief executive officerIl 23Jnj 2113

Robert Bissonnette, MD: Discussing the First Oral IL-23 Inhibitor for Psoriasis

In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis.

Robert bissonnetteInnovaderm researchChief executive officerJnj 2113Il 23

JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis

Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide.

Robert bissonnetteJanssen researchInnovaderm researchHealthday newsNew england journalPsoriasis areaSeverity index

vimarsana © 2020. All Rights Reserved.